Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Jens Wrammert, Kenneth Smith, Joe Miller, William A. Langley, Kenneth Kokko, Christian Larsen, Nai-Ying Zheng, Israel Mays, Lori Garman, Christina Helms, Judith James, Gillian M. Air, J. Donald Capra, Rafi Ahmed and Patrick C. Wilson ()
Additional contact information
Jens Wrammert: Emory University School of Medicine, Atlanta, Georgia 30322, USA
Kenneth Smith: Immunobiology and Cancer Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Joe Miller: Emory University School of Medicine, Atlanta, Georgia 30322, USA
William A. Langley: Emory University School of Medicine, Atlanta, Georgia 30322, USA
Kenneth Kokko: Emory University School of Medicine, Atlanta, Georgia 30322, USA
Christian Larsen: Emory University School of Medicine, Atlanta, Georgia 30322, USA
Nai-Ying Zheng: Immunobiology and Cancer Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Israel Mays: Immunobiology and Cancer Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Lori Garman: Immunobiology and Cancer Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Christina Helms: Immunobiology and Cancer Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Judith James: Arthritis and Immunology Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Gillian M. Air: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
J. Donald Capra: Molecular Immunogenetics Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Rafi Ahmed: Emory University School of Medicine, Atlanta, Georgia 30322, USA
Patrick C. Wilson: Immunobiology and Cancer Research Program, The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA

Nature, 2008, vol. 453, issue 7195, 667-671

Abstract: Monoclonal antibodies: A production boost The use of antibody therapy has been limited in part because fully human monoclonal antibodies (mAbs) targeting specific antigens are difficult to generate. Now by identifying a time window in which the body's immune response to a particular pathogen is at its peak, Wrammert et al. have developed a new technique for the efficient generation of high-affinity human mAbs. In individuals given a booster vaccination against influenza, the number of influenza specific IgG+ antibody-secreting cells in the bloodstream peaks a week after vaccination, accounting for about 6% of all peripheral B cells. By harvesting B cells during this time window, it was possible to produce more than 50 human mAbs that bound to the three target influenza strains with high affinity. The whole procedure took less than a month, which is much quicker that than conventional methods of producing mAbs. The technique should be applicable to any infectious disease for which vaccines are available.

Date: 2008
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature06890 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:453:y:2008:i:7195:d:10.1038_nature06890

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature06890

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().